New drug cocktail aims to beat back head and neck cancer
Disease control
Not yet recruiting
This study tests whether combining the immunotherapy drug camrelizumab with either an EGFR antibody or chemotherapy can help people with advanced head and neck cancer live longer and keep the cancer from coming back. About 246 adults aged 18-75 with stage III-IVb squamous cell ca…
Phase: PHASE3 • Sponsor: Yue He, MD • Aim: Disease control
Last updated May 26, 2026 08:15 UTC